SFG
APLS

Steward Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Steward Financial Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Buy
+4
New +$176 ﹤0.01% 1324

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Steward Financial Group's APLS Position: Q3 2023 in Review

Steward Financial Group opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2023: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1324 among its holdings.

256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Steward Financial Group held 4 shares of Apellis Pharmaceuticals worth $0 as of Q3 2023.
  • Apellis Pharmaceuticals was a new Steward Financial Group position in Q3 2023.
  • Apellis Pharmaceuticals made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1324 holding.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.